Arsenic trioxide phosphorylates c-Fos to transactivate p21WAF1/CIP1 expression

Toxicology and Applied Pharmacology

Volumn 233, Issue 2, 2008, Pages 297-307

  Liu, Zi Miao ^a   Huang, Huei Sheng ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

A431 cells; Arsenic trioxide; c Fos; p21WAF1 CIP1

Indexed keywords

ARSENIC TRIOXIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN C FOS; PROTEIN C JUN; PROTEIN P300; SERINE; STRESS ACTIVATED PROTEIN KINASE; THREONINE; TRANSCRIPTION FACTOR SP1;

AMINO ACID SEQUENCE; ARTICLE; ASSAY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DIMERIZATION; DNA AFFINITY PRECIPITATION ASSAY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN SYNTHESIS; SITE DIRECTED MUTAGENESIS; TRANSACTIVATION;

ARSENICALS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUTAGENESIS, SITE-DIRECTED; OXIDES; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-FOS; TRANSCRIPTIONAL ACTIVATION;

EID: 56049094300     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.08.015     Document Type: Article

References (49)

1. Angel P., and Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim. Biophys. Acta 1072 (1991) 129-157
2. Assoian R.K. Common sense signalling. Nat. Cell Biol. 4 (2002) E187-E188
3. Bossis G., Malnou C.E., Farras R., Andermarcher E., Hipskind R., Rodriguez M., Schmidt D., Muller S., Jariel-Encontre I., and Piechaczyk M. Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation. Mol. Cell. Biol. 25 (2005) 6964-6979
4. Brown P.H., Chen T.K., and Birrer M.J. Mechanism of action of a dominant-negative mutant of c-Jun. Oncogene 9 (1994) 791-799
5. Brown H.J., Sutherland J.A., Cook A., Bannister A.J., and Kouzarides T. An inhibitor domain in c-Fos regulates activation domains containing the HOB1 motif. EMBO J. 14 (1995) 124-131
6. Calcabrini A., Garcia-Martinez J.M., Gonzalez L., Tendero M.J., Ortuno M.T., Crateri P., Lopez-Rivas A., Arancia G., Gonzalez-Porque P., and Martin-Perez J. Inhibition of proliferation and induction of apoptosis in human breast cancer cells by lauryl gallate. Carcinogenesis 27 (2006) 1699-1712
7. Chen L.C., Chen B.K., and Chang W.C. Activating protein 1-mediated cyclooxygenase-2 expression is independent of N-terminal phosphorylation of c-Jun. Mol. Pharmacol. 67 (2005) 2057-2069
8. Datto M.B., Yu Y., and Wang X.F. Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. J. Biol. Chem. 270 (1995) 28623-28628
9. Derijard B., Hibi M., Wu I.H., Barrett T., Su B., Deng T., Karin M., and Davis R.J. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76 (1994) 1025-1037
10. Dilda P.J., and Hogg P.J. Arsenical-based cancer drugs. Cancer Treat. Rev. 33 (2007) 542-564
11. Efferth T., Li P.C., Konkimalla V.S., and Kaina B. From traditional Chinese medicine to rational cancer therapy. Trends Mol. Med. 13 (2007) 353-361
12. Funk M., Poensgen B., Graulich W., Jerome V., and Muller R. A novel, transformation-relevant activation domain in Fos proteins. Mol. Cell. Biol. 17 (1997) 537-544
13. WAF1/CIP1 gene. Exp. Cell Res. 246 (1999) 280-289
14. Goulet A.C., Chigbrow M., Frisk P., and Nelson M.A. Selenomethionine induces sustained ERK phosphorylation leading to cell-cycle arrest in human colon cancer cells. Carcinogenesis 26 (2005) 109-117
15. Harper J.W., Adami G.R., Wei N., Keyomarsi K., and Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75 (1993) 805-816
16. Huang H.S., Chang W.C., and Chen C.J. Involvement of reactive oxygen species in arsenite-induced downregulation of phospholipid hydroperoxide glutathione peroxidase in human epidermoid carcinoma A431 cells. Free Radic. Biol. Med. 33 (2002) 864-873
17. WAF1/CIP1 activation involved in the arsenic trioxide-induced human epidermoid carcinoma A431 cellular cytotoxicity. J. Biomed. Sci. 13 (2006) 113-125
18. Hughes M.F. Arsenic toxicity and potential mechanisms of action. Toxicol. Lett. 133 (2002) 1-16
19. Jacks T., and Weinberg R.A. Cell-cycle control and its watchman. Nature 381 (1996) 643-644
20. Johnson G.L., and Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298 (2002) 1911-1912
21. WAF1/Cip1 gene by acting as a superactivator of the ubiquitous transcription factor Sp1. J. Biol. Chem. 274 (1999) 29572-29581
22. Karin M., Liu Z., and Zandi E. AP-1 function and regulation. Curr. Opin. Cell Biol. 9 (1997) 240-246
23. Kligerman A.D., and Tennant A.H. Insights into the carcinogenic mode of action of arsenic. Toxicol. Appl. Pharmacol. 222 (2007) 281-288
24. Kwok T.T., Mok C.H., and Menton-Brennan L. Up-regulation of a mutant form of p53 by doxorubicin in human squamous carcinoma cells. Cancer Res. 54 (1994) 2834-2836
25. LaBaer J., Garrett M.D., Stevenson L.F., Slingerland J.M., Sandhu C., Chou H.S., Fattaey A., and Harlow E. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11 (1997) 847-862
26. WAF1/CIP1 expression in human epidermoid carcinoma A431 cells. Cell. Signal. 18 (2006) 244-255
27. WAF1/CIP1 expression. J. Biomed. Sci. 15 (2008) 333-342
28. Liu B., Pan S., Dong X., Qiao H., Jiang H., Krissansen G.W., and Sun X. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci. 97 (2006) 675-681
29. Monje P., Marinissen M.J., and Gutkind J.S. Phosphorylation of the carboxyl-terminal transactivation domain of c-Fos by extracellular signal-regulated kinase mediates the transcriptional activation of AP-1 and cellular transformation induced by platelet-derived growth factor. Mol. Cell. Biol. 23 (2003) 7030-7043
30. Murphy L.O., and Blenis J. MAPK signal specificity: the right place at the right time. Trends Biochem. Sci. 31 (2006) 268-275
31. Murphy L.O., Smith S., Chen R.H., Fingar D.C., and Blenis J. Molecular interpretation of ERK signal duration by immediate early gene products. Nat. Cell Biol. 4 (2002) 556-564
32. Ogryzko V.V., Schiltz R.L., Russanova V., Howard B.H., and Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87 (1996) 953-959
33. Pumiglia K.M., and Decker S.J. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 448-452
34. Roovers K., and Assoian R.K. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays 22 (2000) 818-826
35. Sewing A., Wiseman B., Lloyd A.C., and Land H. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol. Cell. Biol. 17 (1997) 5588-5597
36. Shaulian E., and Karin M. AP-1 in cell proliferation and survival. Oncogene 20 (2001) 2390-2400
37. Smith A.H., Lopipero P.A., Bates M.N., and Steinmaus C.M. Public health. Arsenic epidemiology and drinking water standards. Science 296 (2002) 2145-2146
38. Soucy N.V., Ihnat M.A., Kamat C.D., Hess L., Post M.J., Klei L.R., Clark C., and Barchowsky A. Arsenic stimulates angiogenesis and tumorigenesis in vivo. Toxicol. Sci. 76 (2003) 271-279
39. Straub A.C., Stolz D.B., Vin H., Ross M.A., Soucy N.V., Klei L.R., and Barchowsky A. Low level arsenic promotes progressive inflammatory angiogenesis and liver blood vessel remodeling in mice. Toxicol. Appl. Pharmacol. 222 (2007) 327-336
40. Sutherland J.A., Cook A., Bannister A.J., and Kouzarides T. Conserved motifs in Fos and Jun define a new class of activation domain. Genes Dev. 6 (1992) 1810-1819
41. Tang D., Wu D., Hirao A., Lahti J.M., Liu L., Mazza B., Kidd V.J., Mak T.W., and Ingram A.J. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J. Biol. Chem. 277 (2002) 12710-12717
42. Tanos T., Marinissen M.J., Leskow F.C., Hochbaum D., Martinetto H., Gutkind J.S., and Coso O.A. Phosphorylation of c-Fos by members of the p38 MAPK family. Role in the AP-1 response to UV light. J. Biol. Chem. 280 (2005) 18842-18852
43. Whitmarsh A.J., Shore P., Sharrocks A.D., and Davis R.J. Integration of MAP kinase signal transduction pathways at the serum response element. Science 269 (1995) 403-407
44. Woods D., Parry D., Cherwinski H., Bosch E., Lees E., and McMahon M. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol. Cell. Biol. 17 (1997) 5598-5611
45. Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin. Cancer Res. 10 (2004) 3815-3824
46. Xiao D., and Singh S.V. Phenethyl isothiocyanate-induced apoptosis in p53-deficient PC-3 human prostate cancer cell line is mediated by extracellular signal-regulated kinases. Cancer Res. 62 (2002) 3615-3619
47. Yamamoto T., Ebisuya M., Ashida F., Okamoto K., Yonehara S., and Nishida E. Continuous ERK activation downregulates antiproliferative genes throughout G1 phase to allow cell-cycle progression. Curr. Biol. 16 (2006) 1171-1182
48. Yu H.S., Liao W.T., and Chai C.Y. Arsenic carcinogenesis in the skin. J. Biomed. Sci. 13 (2006) 657-666
49. Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol. 3 (2001) 245-252